APAC Point of Care (POC) Diagnostics/Testing Market

APAC POC Diagnostics Market Size (2023 to 2028)

The Asia Pacific Point of Care Testing Market size was worth USD 4.41 billion in 2023 and estimated to reach USD 7.19 billion by the end of 2028, with a CAGR of 10.28%.

Point-of-care diagnostics allow a speedy, convenient, and cost-efficient way to diagnose diseases at healthcare centers and hospitals. The point-of-care diagnosis is a term collectively used for diagnostic procedures and tests performed on-site. As compared to conventional in-laboratory tests, point-of-care diagnostics have the advantage of speed and convenience without compromising on consistency. Point-of-care diagnostics help cut down on the need for sophisticated diagnostic systems for regular tests like blood tests and urine tests.

Many advanced points of care diagnostic products are on the verge of being used practically and widely. More than innovative and advanced point-of-care devices, there is a great need for inexpensive solutions that can be set up in regions where infectious diseases are highly prevalent. In developing areas, these tests are crucial in counterbalancing the lack of adequate laboratory capacity. It is one of the most promising opportunities that can be grabbed by market players.

To provide effective and fast diagnostic results, clinics and other healthcare establishments are opting for the point-of-care test, consequently influencing industrial growth. Advances in technology and the introduction of cost-effective and high-quality medical solutions to achieve miniaturization and lab automation are expected to serve the point-of-care diagnostics market as a vital driver. Additionally, healthcare practitioners have been increasingly more open and willing to adopt point-of-care diagnostic consumables and medical devices, thereby resulting in rapid demand and growth of this market.

However, there are some certain market restraints that players need to overcome. The effort and coordination required among healthcare centers, researchers, practitioners, and manufacturers are the most significant restraining factor for the growth of the point-of-care diagnostics market. Also, reluctance from the industry towards changing the existing norms, many products recalls, stringent regulatory framework, and unfavorable reimbursement scenario are some of the challenges faced by the point-of-care diagnostics market.

This market research report on the APAC POC Diagnostics Market has been segmented and sub-segmented into the following categories and analyzed market size and forecast until 2025.

By Product: 

• Infectious Diseases
• Cardiac Markers
• Oncology Markers
• OTC Diagnostic Tests
• Drugs Of Abuse
• Blood Gas Testing
• Fertility Testing
• Urinalysis
• Coagulation
• Hematology
• Glucose Monitoring
• Ambulatory Chemistry
• Decentralized Clinical Chemistry

By End-User: 

• Clinics
• Hospitals
• Home Healthcare
• Ambulatory Care Settings
• Laboratories

By Country: 

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Regionally, emerging markets such as China and India offer high growth potential for companies involved in developing and distributing point-of-care diagnostic devices. Increasing initiatives by market players, a growing patient population base, and a rise in the number of partnerships and joint ventures among point-of-care providers are the key factors driving the growth of the point-of-care diagnostics market in emerging countries.

Key market participants leading the APAC POC testing market are Abbott Laboratories, Inc., Danaher Corporation, Roche Diagnostics Limited, BioMerieux, Siemens Healthcare, Beckman Coulter, Inc., Becton, Dickinson and Company, Johnson & Johnson, Alere Inc., and PTS Diagnostics.